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Original Article
Diagnosis and treatment of patients with
antiphospholipid syndrome: a mixed-method
evaluation of care in The Netherlands
Mirthe J Klein Haneveld 1, Caro H.C. Lemmen1, Tammo E. Brunekreef 1,
Marc Bijl2, A.J. Gerard Jansen3, Karina de Leeuw4, Julia Spierings 1 and
Maarten Limper 1; for the ARCH Study Group
Abstract
Objectives. The aims were to gain insight into the care provided to patients with APS in The
Netherlands and to identify areas for improvement from the perspective of both patients and medical
specialists.
Methods. APS care was evaluated using qualitative and quantitative methods. Perspectives on APS
care were explored using semi-structured interviews with medical specialists, patient focus groups and
a cross-sectional, online patient survey. In order to assess current practice, medical records were
reviewed retrospectively to collect data on clinical and laboratory manifestations and pharmacological
treatment in six Dutch hospitals.
Results. Fourteen medical specialists were interviewed, 14 patients participated in the focus groups
and 79 patients completed the survey. Medical records of 237 patients were reviewed. Medical record
review showed that only one-third of patients were diagnosed with APS within 3 months after entering
specialist care. The diagnostic approach and management varied between centres and specialists.
Almost 10% of all patients and 7% of triple-positive patients with thrombotic APS were not receiving
any anticoagulant treatment at the time of medical record review. Correspondingly, poor recognition
and fragmentation of care were reported as the main problems by medical specialists. Additionally,
patients reported the lack of accessible, reliable patient education, psychosocial support and trust in
physicians as important points for improvement.
Conclusion. Delayed diagnosis, variability in management strategies and fragmentation of care were
important limitations of APS care identified in this study. A remarkable 10% of patients did not receive
any anticoagulant treatment.
Key words: antiphospholipid syndrome, quality of care, qualitative research, medical records, unmet patient
needs
Introduction
The APS is a rare autoimmune disease affecting 1000–
2000 patients in The Netherlands [1, 2]. A diagnosis of
APS is generally made when a patient meets the classi-
fication criteria: vascular thrombosis and/or pregnancy
morbidity, such as repeated spontaneous abortion,
unexplained fetal death and preterm birth, in the re-
peated presence of circulating aPL targeted at aCL and/
or b2-glycoprotein I (b2GPI) and/or lupus anticoagulant
(LAC) with an interval of 12 weeks [1, 2]. APS is
associated with a variety of non-criteria clinical manifes-
tations, such as thrombocytopenia, renal
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microangiopathy, heart valve disease, livedo reticularis
and migraine [1, 2]. It often occurs in isolation, but can
be found in association with SLE and other autoimmune
diseases [1, 2]. Lifelong anticoagulation is the mainstay
of therapy for thrombotic APS owing to the high risk of
relapse; for obstetrical APS, treatment exists of low-
dose aspirin and prophylactic low-molecular-weight
heparin during pregnancy [2, 3]. Additionally, immuno-
modulatory drugs, such as HCQ, are recommended for
secondary APS in SLE patients [2, 3]. Optimal care for
APS is challenging because of its rare occurrence, varia-
tion in diagnostic test assays and interpretation, hetero-
geneous clinical manifestations and subsequent
multidisciplinary character. A review of clinical practice
guidelines concluded that a formal guideline covering all
relevant aspects of APS diagnosis and treatment is
missing [4]. Given that large randomized controlled trials
for treatment of APS are rarely performed, the develop-
ment of evidence-based guidelines, such as the 2019
EULAR recommendations for the management of APS,
remains very challenging [3, 4]. As a consequence, vari-
ation in treatment strategies between medical specialists
and centres is, presumably, high [2–4].
Few studies have investigated the experiences re-
garding APS care of patients and physicians. A ques-
tionnaire distributed among patients in the UK pointed
out that there was a long delay between first symptoms
and diagnosis, with a median duration of 3 years, in ad-
dition to a lack of awareness of APS among general
practitioners and medical specialists [5]. Qualitative
studies into experiences of APS patients described the
impact of living in uncertainty and delayed diagnosis [6–
8]. Patient representatives highlighted the need for im-
proved patient education and monitoring [4]. However,
these unmet patient needs require more research atten-
tion [4–8].
The Dutch Arthritis Research and Collaboration Hub
(ARCH) aims to improve care for rare autoimmune dis-
eases, including APS [2]. Using both qualitative and
quantitative methods, the aims of the present study
were to gain insight into the care currently provided to
patients with APS in The Netherlands and to identify
unmet needs and areas for improvement from the per-
spectives of patients and medical specialists from differ-
ent centres and disciplines.
Methods
Design
This study adopted a mixed-method design to collect
qualitative and quantitative data from the perspectives
of patients and medical specialists. We collected data in
three stages. Firstly, qualitative data were collected from
focus group sessions with patients and interviews with
medical specialists. Secondly, an online survey was dis-
tributed among patients. Thirdly, medical records in uni-
versity and general hospitals were reviewed to evaluate
variation in patient characteristics, the diagnostic pro-
cess and management between centres. Ethical ap-
proval was given by the Medical Ethical Committee of
the University Medical Centre Utrecht (METC number
18-508) and all participating hospitals.
Setting and participants
Twenty medical specialists known to have a special in-
terest in thrombotic conditions were invited to partici-
pate in individual interviews between June and
September 2018. Medical specialists were selected by
three ARCH APS working group members in order to
reach a heterogeneous sample with regard to sex, disci-
pline (neurology, haematology, clinical immunology,
rheumatology, gynaecology and vascular medicine), pa-
tient load and type of hospital in The Netherlands. All
interviews with medical specialists were held by tele-
phone by the same researcher (J.S.) and lasted between
30 and 75 min. The researcher (female, rheumatologist,
researcher) was not affiliated with the participants.
Patients with APS were recruited to participate in fo-
cus groups by the national patient organization
[Nationale Vereniging voor Lupus, APS, Sclerodermie en
MCTD (NVLE)]. Four focus group sessions, with three or
four participants per group, took place between June
and November 2018 at a meeting point centrally located
in the country. Before the focus group, participants were
asked to fill out a questionnaire on sociodemographic
information and disease characteristics. All focus groups
were moderated by one researcher (J.S.) in the pres-
ence of a representative of the patient organization and
lasted between 120 and 150 min.
Medical specialists from four university hospitals
[University Medical Centre Utrecht (UMCU), Erasmus
Medical Centre Rotterdam (EMC), Universal Medical
Centre Groningen (UMCG) and Maastricht University
Medical Centre (MUMC)] and three general hospitals
[Diakonessenhuis Utrecht, Hospital Group Twente (ZGT)
Key messages
. Delayed diagnosis is common among patients with APS.
. APS treatment strategies vary between medical specialists and hospitals.
. Unmet APS patient needs include patient education, psychosocial support and trust in physicians.
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Almelo/Hengelo and Martini Hospital Groningen] invited
a total of 109 patients by mail to participate in the online
self-administered survey. The inclusion criterion was a
clinical diagnosis of APS according to their medical spe-
cialist. Patients could sign up for participation by send-
ing an email to the researcher with their consent.
Subsequently, they received a link to the survey in
Castor Electronic Data Capture (EDC) [9]. The survey
was open from November 2018 until June 2019.
Between March and May 2019, medical records from
four university hospitals (UMCU, EMC, UMCG and
MUMC) and two general hospitals (Diakonessenhuis
Utrecht and ZGT) were reviewed. Each centre compiled
a list of patients for whom aPL measurement was
requested at the laboratory. Patients were randomly se-
lected from this list and included in the study if the fol-
lowing inclusion criteria were met: a clinical diagnosis of
APS according to the coordinating physician; and avail-
ability of data regarding APS in the patient record.
Inclusion of patients continued until a maximum of 50
patients was reached or no new APS patients could be
identified.
Data collection
Two rheumatologists and a clinical immunologist formu-
lated an interview guide for semi-structured interviews.
It was tested by an advisory group consisting of patients
and medical specialists of the ARCH APS working group
(Supplementary Material, section Interview Guide, avail-
able at Rheumatology Advances in Practice online) A
semi-structured approach was chosen because it en-
sured that all topics were addressed but left room for
flexibility in pursuing participants’ interests and expertise
[10]. The focus groups had a similar semi-structured ap-
proach. The diagnostic process, management after di-
agnosis, provision of information and psychosocial
support were addressed. Participants were asked to
share the main challenges and unmet needs and to sug-
gest relevant process and outcome measures that
should be used as quality indicators for APS care. The
interviews and focus group sessions were recorded and
transcribed verbatim by three independent researchers
(M.J.K.H., C.H.C.L. and ’J.S.).
Data collection for the online survey and medical re-
cord review was done in Castor EDC [9]. The online sur-
vey was composed and tested in a similar manner to
the interview guide (Supplementary Material, section
Online Survey, available at Rheumatology Advances in
Practice online). Data for medical record review were
collected using a case report form. The relevant process
and outcome measures mentioned in focus groups and
interviews were incorporated into the case report form
(Supplementary Table S1, available at Rheumatology
Advances in Practice online). The data collected in-
cluded demographic information, duration of illness,
time until diagnosis, clinical and laboratory criteria of
APS, non-criteria disease manifestations, medication
use, complications of treatment and information regard-
ing disease management.
Data analysis
Two independently working researchers (M.J.K.H. and
C.H.C.L.) analysed the data from interviews and focus
group sessions mostly in a deductive fashion [11]. The
researchers first familiarized themselves with the data
by thoroughly reading the transcripts and writing down
initial ideas. Themes were identified using the interview
guide. Additionally, topics that were frequently brought
up by participants were considered as themes or sub-
themes. Subsequently, the two researchers discussed
the identified themes and assessed their internal homo-
geneity and external heterogeneity. The results were
summarized by the two researchers, discussed in the
ARCH APS working group and used to compose the
questions for the survey. The consolidated criteria for
reporting qualitative research (COREQ) are reported in
Supplementary Table S2, available at Rheumatology
Advances in Practice online [12].
Quantitative data were processed using IBM SPSS
Statistics for Windows, v.25.0.
Results
Specialist interviews, patient focus groups and
patient survey
Characteristics of study participants
Of the 20 invited medical specialists, four did not re-
spond and two did not want to participate owing to time
limitations. The characteristics of 14 interviewed medical
specialists are displayed in Table 1. For the online survey,
109 patients were invited; the response rate was 72.5%.
Demographic and clinical characteristics and the experi-
ences of 14 focus group participants and 79 patients
who filled out the digital survey are described in Table 2.
Perspectives on the diagnostic process
The importance of being taken seriously by medical spe-
cialists and general practitioners and the necessity of re-
ferral to expert centres were recurring themes in the
focus groups and survey responses. Several patients felt
that they were ‘being fobbed off’ by physicians; two fo-
cus group participants remarked that their health prob-
lems had been interpreted initially as psychosomatic.
Self-reported time to diagnosis in focus groups and sur-
vey responses varied widely, ranging from <1 month to
>5 years. Overall, the time to diagnosis had a strong neg-
ative impact on satisfaction with the diagnostic process
among the focus group participants. However, only 7.6
and 8.9% of survey respondents considered delayed di-
agnosis and, respectively, insufficient recognition of APS
by physicians to be the main obstacles in APS care.
According to medical specialists, the main challenges
in the diagnostic process are insufficient recognition of
APS by medical specialists (10/14) and general practi-
tioners (7/14) in addition to the absence of evidence-
based diagnostic guidelines (3/14). One specialist con-
sidered the quality of laboratory diagnostics to be a
main challenge. Four medical specialists remarked that










roningen user on 25 N
ovem
ber 2020
the diagnostic process of APS requires more expertise
compared with the management of APS after diagnosis.
Perspectives on management after diagnosis
Patients felt the need to orchestrate their own care, be-
cause they experienced a lack of collaboration and
communication between medical specialists and be-
tween medical specialists and medical services, i.e. the
anticoagulation service (Dutch: Trombosedienst). This
made them as patients responsible for an adequate ex-
change of information about their disease and medica-
tion use, which could be particularly worrisome for
patients when they were critically ill and required emer-
gency care. Several participants expressed the need for
a document explaining their condition to show at emer-
gency departments. Correspondingly, limitations in the
exchange of patient information between hospitals were
mentioned as a burden by 50% of the interviewed medi-
cal specialists.
Another main challenge in APS care reported by 8
of 14 medical specialists was the lack of evidence-
based treatment guidelines. The absence of uniform
guidelines was thought to contribute to variation in
treatment strategies and to have a negative impact
on the quality of care. Patients recognized this issue
and referred to uncertainty regarding the management
of anticoagulation in the context of surgical
procedures.
Ten medical specialists agreed that multidisciplinary
consultation should be possible for all patients; how-
ever, only six reported that this was available at their
hospital. Twelve medical specialists agreed to the state-
ment that APS care is fragmented; eight agreed that im-
proved communication is necessary to improve
cooperation between physicians.
Perspectives on information provision, psychosocial
support and daily functioning
Patient education was considered to be insufficient by
8 of 14 interviewed medical specialists, 11 of 14 focus
group participants and 41.8% of survey respondents.
Patients identified this as a big challenge in APS care
and a good measure for quality of care. Patients par-
ticularly needed information about the wide range of
symptoms attributed to APS, the impact of APS on
daily life and prognostic information. A key provider of
patient information and support is the patient organi-
zation for APS, although 3 of 14 medical specialists
and 38.0% of survey respondents were unfamiliar with
this organization. Some patients and medical special-
ists proposed that specialized nurses might assist in
patient education.
A minority of focus group participants and survey
respondents (16.5%) was offered psychological assis-
tance after diagnosis, although more than half of
respondents would have welcomed this support.
According to interviewed medical specialists, a lack of
time, not being the coordinating physician and no ap-
parent need for psychosocial assistance were barriers
to the provision of psychosocial support.
The last unmet need identified in APS care was the
need for support in coping with limitations in daily func-
tioning (reported by 54.4% of survey respondents) and
support with occupational hurdles. Focus group partici-
pants therefore included employment status and satis-
factory daily functioning as important outcomes to
measure in APS care.
Fig. 1 summarizes the relevant areas for improvement
as reported by medical specialists and survey respond-
ents. Participant quotations are provided in
Supplementary Table S3, available at Rheumatology
Advances in Practice online.
TABLE 1 Demographic characteristics of interviewed specialists (n¼14)
Characteristic Value
Specialty, n (%)
Clinical immunologist 3 (21.4)





Age median (range), years (n ¼12) 44 (37–58)
Hospital type, n (%)
University hospital 9 (64.3)






















Clinical and laboratory criteria and diagnostic process
Medical records of 237 patients were reviewed.
Demographic, clinical and laboratory characteristics are
displayed in Table 3. Of all patients, 70.9% had throm-
bosis, 40.2% experienced obstetric complication(s) and
22.4% experienced both. In 9.3% of patients there were
no thrombotic or obstetric events, but a diagnosis of
APS was made because of non-criteria manifestations.
The median number of recorded non-criteria manifesta-
tions was 1.0 (interquartile range 0.0–2.0, range 0.0–5.0).
The most common non-criteria manifestations were
thrombocytopenia (25.3%), pre-eclampsia/haemolysis,
elevated liver enzymes and low platelets syndrome
(13.4% of female patients), livedo reticularis (12.7%), mi-
graine (11.8%) and valvular heart disease (10.1%).
aPL were elevated in 92.4% of patients: aCL, LAC
and anti-b2GPI antibodies were detected in 75.1, 51.9
and 48.1%, respectively. In 7.6% of patients, seroneg-
ativity for all measured aPL was described. Fifty-five
patients (23.6%) were ‘triple positive’, of whom 42 ex-
perienced thrombotic manifestations and 13 had ob-
stetric APS. In 84.3% of laboratory measurements,
aPL status was assessed in at least two separate
samples.
The median duration between the first recorded dis-
ease manifestation and receiving specialist care was










Age, median (range) 46 (27–65) 53 (26–77)
Sex, n (%) Female 13 (92.9) 68 (86.1)





4 (28.6) 45 (57.0)
Higher professional or
university educationa
10 (71.4) 34 (43.0)
Treatment centre, n (%) University hospital 7 (50.0) 67 (84.8)
General hospital 5 (35.7) 6 (7.6)
Other/do not knowb 2 (14.3) 6 (7.6)
Duration of disease, median
(range), years
6.5 (0–22) 7 (1–27)
Duration of symptoms
before diagnosis, n (%)
>5 years 3 (21.4%) 29 (36.7)
3–5 years 0 (0.0) 4 (5.1)
2–3 years 3 (21.4) 3 (3.8)
1 year 0 (0.0) 5 (6.3)
6 months 1 (7.1) 8 (10.1)
<6 months 4 (28.6) 11 (13.9)
Do not know 3 (21.4) 19 (24.1)
Other rheumatological
disease, n (%)
No, primary APS 7 (50.0) 33 (41.7)
SLE 6 (42.8) 21 (26.6)
Other/do not knowc 1 (14.2) 25 (31.6)
Manifestations of disease, n (%) Deep venous thrombosis 3 (21.4) 37 (46.8)
Cerebrovascular accident 5 (35.7) 23 (29.1)
Transient ischaemic attack 3 (21.4) 18 (22.7)
Obstetric manifestation 3 (21.4) 30 (38.0)
Thrombocytopenia 1 (7.1) 11 (13.9)
Livedo reticularis 5 (35.7) 10 (12.7)
Endocarditis 1 (7.1) 5 (6.3)
Migraine 6 (42.8) 12 (15.2)
Other 7 (50.0) 18 (22.8)
Experienced limitation
owing to APS, n (%)
Work 6 (42.8) 40 (50.6)
Travel 8 (57.1) 34 (43.0)
Daily functioning 6 (42.8) 43 (54.4)
aHigher professional or university education is defined as Dutch higher vocational training (HBO) or university level.
Secondary vocational training or less is defined as Dutch secondary vocational training (MBO), secondary education (VWO,
HAVO, VMBO) or primary education. bNot under treatment at any medical hospital or shared care between multiple hospi-
tals. cAmong others: SS, RA.
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0 months. The median time until diagnosis after entering
specialist care was 6 months (interquartile range 2–
24 months). In 32.1% of patients, the diagnosis of APS
was established within 3 months.
Management after diagnosis
In 81.8% of patients, the coordinating physician could
be identified from medical case records; this was most
often a rheumatologist/internist clinical immunologist
(39.7%) or general internist (28.7%). In 18.2% of
patients, the coordinating physician could not be identi-
fied from the medical record or patients were not under
regular follow-up with any medical specialist.
Gynaecologists, neurologists and haematologists were
frequently involved in the diagnostic process and man-
agement (in 36.7, 34.6 and 23.2%, respectively), but
were less often the coordinating physician (in 4.2, 0.4
and 4.2%, respectively). The number of medical disci-
plines involved in diagnosis and management was one
in 19.4%, two in 38.4%, three in 21.9% and four or
more in 20.3% of patients. In 45.6% of case, patients
were discussed in a multidisciplinary consultation meet-
ing. A specialized nurse was involved with 14.8% of
patients.
In Fig. 2, pharmacological management is displayed.
Most patients were treated using vitamin K antagonists,
HCQ and/or carbasalate calcium/ascal. No anticoagu-
lant treatment was provided in 9.3% of all patients. This
was the case in 5 of 42 triple positive patients, of whom
3 had thrombotic APS (7.1%) with an indication for life-
long anticoagulation.
In 26.2% of patients, a next thrombotic or obstetric
event occurred after diagnosis. Complications of treat-
ment occurred in 25.4%: bleeding and intolerance of
medication were reported in 20.3 and 12.5%, respec-
tively. End-organ damage, including permanent ischae-
mic events, neurological damage, amputation,
catastrophic APS and heart or renal failure, was de-
scribed in 24.5%.
Fitness for work was often not reported in medical
records (47.2%). Of all patients, 28.7, 11.4 and 12.7%
were demonstrated to be fully, partly fit or unfit for work,
respectively.
Discussion
In this mixed-method study, we evaluated current health
care for patients with APS in The Netherlands. Delayed
diagnosis, variation in management strategies and
unmet needs with regard to patient education and self-
management among APS patients were observed.
Recommendations for improving APS care are provided
in Fig. 3.
Both patients and medical specialists identified poor
recognition of APS and, consequently, delayed diagno-
sis as a major obstruction to quality of care. The self-
reported duration between the onset of any symptoms
and diagnosis exceeded 5 years in more than one-third
of patients. Moreover, only one-third of patients in-
cluded in medical record review were diagnosed with
APS within 3 months after entering specialist care.
These findings are in line with previous research de-
scribing a long diagnostic delay in APS, during which
patients experience uncertainty about their health [5, 6].
Our study found a median delay of 0 months between
the first recorded disease manifestation and receiving
specialist care; we hypothesize that this is because the
event leading to specialist referral is often registered as
the first disease manifestation. A cross-sectional
Mexican study including 176 APS patients found that in
patients who experienced both thrombosis and a non-
criteria manifestation, non-criteria manifestations pre-
dated the first thrombotic event in 28.7% [13]. Non-
criteria manifestations, such as thrombocytopenia, pre-
eclampsia/haemolysis, elevated liver enzymes and low
platelets syndrome, livedo reticularis, migraine and val-
vular heart disease, all occurred in >10% of patients in-
cluded in our study and might still be under-reported;
these manifestations might thus both contribute to the
diagnosis of APS and significantly influence the clinical
condition of patients with APS.
Another remarkable finding was the variability in man-
agement strategies. Although recent consensus papers
aim to support physicians in daily clinical decision-
making, low quality and uptake of recommendations
posed a major challenge according to interviewed medi-
cal specialists [2–4]. In our study, a considerable
FIG. 1 Areas for improvement in APS care according to medical specialists and patients resulting from survey
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TABLE 3 Demographic, clinical and laboratory characteristics of patients included in medical record review
Patient characteristics University hospitals
(n 5 192)
General
hospitals (n 5 45)
All patients (n 5 237)
Age, mean, S.D., years 46 13 49 15 47 13
Duration of disease, median, IQR, years (n ¼235) 6 2–14 3 2–8 5 2–14
Sex, % Male 15.1 31.1 18.1
Female 84.9 68.9 81.9
Type of APS, % Primary APS 61.5 86.7 66.2
Secondary APS 38.5 13.3 33.8
Of which SLE (n ¼52) 76.5 80.0 76.8
Treatment centre, % University hospital 81.0
General hospital 19.0
Deceased, % 2.1 2.2 2.1
Time until diagnosis Median IQR n
Duration until under specialist
treatment, months
All patients 0.0 0.0–3.0 212
University hospital 0.0 0.0–3.0 171
General hospital 0.0 0.0–2.0 41
Duration under specialist
treatment until diagnosis, months
All patients 6.0 2.0–24.0 218
University hospital 7.0 2.0–24.0 175
General hospital 4.0 1.0–12.0 43
Diagnosed with APS within
3 months after entering specialist
care, %, n
All patients 34.9 218
University hospital 32.6 175













Vascular thrombosis, % 72.9 62.2 70.9
Number of events, median
(IQR) (n ¼ 168)
2.0 (1.0–3.0) 1.0 (1.0–2.0) 2.0 (1.0–3.0)
Obstetric complication(s) 42.2 17.8 40.2
Number of events, median
(IQR) (n ¼100)
1.0 (1.0–2.0) 2.0 (1.0–3.0) 1.0 (1.0–3.0)








Thrombocytopenia, % 26.0 22.2 25.3
Livedo reticularis, % 14.1 6.7 12.7
Migraine, % 12.0 11.1 11.8
Pre-eclampsia/HELLP syndrome,
%; % females
13.0; 15.3 2.2; 3.2 11.0; 13.4
Valvular heart disease, % 10.9 6.7 10.1
Cutaneous ulceration, % 8.9 2.2 7.6
Insult, % 7.8 2.2 6.8
aPL-related nephropathy, % 4.7 4.4 4.6
Chorea, % 3.1 0 2.5
Superficial venous thrombosis, % 2.6 0 2.1
Intra-uterine growth retardation,
%; % females
2.6; 3.1 0 2.1; 2.6
Laboratory criteria LAC Prevalence, % 53.1 44.4 51.5
Assessed in 2 samples,
% (n ¼ 122)
78.4 85.0 79.5
aCL Prevalence, % 79.2 57.8 75.1
Assessed in 2 samples,
% (n ¼ 178)
89.5 84.6 88.8
Anti-b2GP Prevalence, % 47.9 48.9 48.1
Assessed in 2
samples, % (n ¼ 114)
85.8 72.7 82.5
Seronegative for all 3 aPL, % 7.8 6.7 7.6
(continued)
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percentage of patients was not treated according to the
latest insights. In 9.3% of patients, no anticoagulant
treatment or treatment plan in case of pregnancy was
provided at the time of medical record review; in partic-
ular, 7.1% of triple positive patients with thrombotic
APS, bearing the highest risk of recurrent thrombosis,
did not receive any anticoagulant treatment [2, 3].
Moreover, 4.2% of patients were treated with direct oral
anticoagulants, which might be associated with a higher
risk of recurrent thrombosis in APS [14]. In our study,
the reasons underlying treatment decisions were not de-
rived from medical records. Given that no bleeding com-
plications were recorded in patients who did not receive
anticoagulant treatment, previous adverse events are an
FIG. 3 Recommendations for APS care in The Netherlands
FIG. 2 Pharmacological management of patients included in medical record review
Patients who received multiple medication types for management of APS count towards all received mentioned medi-
cations. DOAC: direct oral anticoagulant; LMWH: low-molecular-weight heparin; Other: amongst others, plasmaphere-

















elevated aPL, median (IQR)
2.0 (2.0–2.5) 1.0 (1.0–2.0) 2.0 (1.0–2.0)
Total number of positive
clinical and
laboratory criteria, median (IQR)
3.0 (2.0–4.0) 2.0 (2.0–3.0) 3.0 (2.0–4.0)
b2GPI: anti-b2-glycoprotein I antibodies; HELLP: haemolysis, elevated liver enzymes and low platelets; IQR: interquartile
range; LAC: lupus anticoagulant.
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unlikely reason for not prescribing medication. We hy-
pothesize that unawareness among physicians might
play a role in the variation in treatment. Furthermore,
fragmentation of care results in challenges in communi-
cation between medical specialists within and between
hospitals. Fragmentation of care is a well-documented
problem in other rare and systemic diseases [15].
Lastly, we identified unmet patient needs in current
health care. The most reported need was patient educa-
tion about the disease and self-management support
with regard to daily activities, work and psychological
wellbeing. This need is reaffirmed by previous studies
describing the impact of the disease on daily life in APS
patients and, specifically, how the lack of knowledge
about the disease results in uncertainty and stress [7, 8].
Previous research in other rare diseases likewise high-
lights patient education and provision of non-
pharmacological care, such as psychological support,
as a key need [4, 15–17]. Although several patients and
medical specialists proposed that specialized nurses
might play a role in providing reliable information and
self-management support, nurses were involved with
only a small proportion of patients.
A second important unmet need of patients was trust
in physicians in general, because patients experienced
that some medical specialists and general practitioners
were unfamiliar with APS. Patients therefore felt the
need to orchestrate their own care, such as taking an
active role in organizing exchange of medical documen-
tation between medical specialists, demanding diagnos-
tic tests and proposing management strategies. This
type of patient-directed interaction has been described
previously as a widely experienced communication pat-
tern among patients with rare diseases [18].
Remarkably, 10 of 14 focus group participants have re-
ceived higher education; given that more than one-third
of the Dutch population has limited health literacy, this
level of control over disease management might not be
achievable for all patients, potentially resulting in de-
creased quality of care [19]. Initiatives were proposed to
bridge knowledge gaps, such as the provision of a doc-
ument that explains APS and that can be used in emer-
gency situations.
Our study has some limitations. Firstly, there could be
selection bias, because a large proportion of included
patients completed higher education and was treated at
university hospitals. Secondly, only patients who were
either familiar with the patient organization and able to
travel or able use electronic communication methods
could participate in the focus groups and survey, re-
spectively. Therefore, the results might not be generaliz-
able to all patients with APS. Thirdly, only medical
specialists known to have a special interest in throm-
botic conditions were interviewed. Lastly, we had to
deal with missing or limited data and potential under-
reporting in medical records. The strength of our study,
however, is that, uniquely, we combined qualitative and
quantitative research methods to evaluate care. To our
knowledge, this is the first study of its kind in the field of
APS. By integrating the perspectives of patients and
medical specialists and medical record data from uni-
versity and general hospitals across the country, it pro-
vides a comprehensive overview of current APS care in
The Netherlands.
In conclusion, the main challenges in APS care in The
Netherlands include delayed diagnosis, low quality and
uptake of evidence-based recommendations, fragmen-
tation of care and a burden placed on patients to or-
chestrate their own care. Unmet patient needs include
patient education, support in daily functioning and trust
in physicians. Despite the high risk of recurrent throm-
bosis, 7.1% of triple positive patients with thrombotic
APS did not receive any anticoagulant treatment.
Probable underlying factors for these challenges include
the rare occurrence and heterogeneous character of
APS. Future research should evaluate the clinical
decision-making process in APS care and continue to
address unmet patient needs. National and multidiscipli-
nary collaboration and continuing education of physi-
cians are required to improve APS care.
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